I am a physician  scientist and I work on the development of new strategies to overcome  resistance to hormonal therapy in ER+HER2- metastatic breast cancer.  Most recently, we have found a target for  metformin in breast cancer and developed a chemical probe for metformin  action, hexyl-benzyl-biguanide (HBB), which is 200-fold more potent.  Cell Chem Biol. 2017 Oct  19;24(10):1259-1275.  My institution is  the Masonic Cancer Center, University of Minnesota; Division of Hematology,  Oncology, and Transplantation, University of Minnesota.  My degrees are S.B. (MIT), M.D., Ph.D.  (Johns Hopkins).